T1	O
and	O
T2	O
Mapping	O
in	O
Recognition	B:C0243095
of	O
Early	O
Cardiac	I:C0243095
Involvement	I:C0243095
in	O
Systemic	O
Sarcoidosis	O
Purpose	O

T1	O
and	O
T2	O
Mapping	O
in	O
Recognition	O
of	O
Early	B:C0243095
Cardiac	I:C0243095
Involvement	I:C0243095
in	O
Systemic	O
Sarcoidosis	O
Purpose	O

To	O
determine	O
whether	O
quantitative	O
tissue	B:C0027061
characterization	O
with	O
T1	O
and	O
T2	O
mapping	O
supports	O
recognition	O
of	O
myocardial	O
involvement	O
in	O
patients	O
with	O
systemic	O
sarcoidosis	O
.	O

To	O
determine	O
whether	O
quantitative	O
tissue	O
characterization	O
with	O
T1	O
and	O
T2	O
mapping	O
supports	O
recognition	B:C0243095
of	O
myocardial	O
involvement	O
in	O
patients	O
with	O
systemic	O
sarcoidosis	O
.	O

To	O
determine	O
whether	O
quantitative	O
tissue	O
characterization	O
with	O
T1	O
and	O
T2	O
mapping	O
supports	O
recognition	O
of	O
myocardial	B:C0027061
involvement	O
in	O
patients	O
with	O
systemic	O
sarcoidosis	O
.	O

Materials	O
and	O
Methods	O
Fifty	O
-	O
three	O
consecutive	O
patients	O
with	O
a	O
biopsy	B:C1304881
-	I:C1304881
proven	I:C1304881
extracardiac	O
diagnosis	I:C0011900
of	O
systemic	O
sarcoidosis	O
(	O
21	O
men	O
;	O
median	O
age	O
,	O
45	O
years	O
;	O
interquartile	O
range	O
,	O
22	O
years	O
)	O
and	O
36	O
normotensive	O
previously	O
healthy	O
control	O
subjects	O
(	O
14	O
men	O
;	O
median	O
age	O
,	O
43	O
years	O
;	O
interquartile	O
range	O
,	O
18	O
years	O
)	O
underwent	O
cardiovascular	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
,	O
which	O
was	O
performed	O
to	O
assess	O
cardiac	O
function	I:C0232164
and	O
late	O
gadolinium	I:C2936236
enhancement	I:C2936236
,	O
and	O
T1	O
and	O
T2	O
mapping	O
.	O

Materials	O
and	O
Methods	O
Fifty	O
-	O
three	O
consecutive	O
patients	O
with	O
a	O
biopsy	O
-	I:C1304881
proven	I:C1304881
extracardiac	B:C0011900
diagnosis	I:C0011900
of	O
systemic	O
sarcoidosis	O
(	O
21	O
men	O
;	O
median	O
age	O
,	O
45	O
years	O
;	O
interquartile	O
range	O
,	O
22	O
years	O
)	O
and	O
36	O
normotensive	O
previously	O
healthy	O
control	O
subjects	O
(	O
14	O
men	O
;	O
median	O
age	O
,	O
43	O
years	O
;	O
interquartile	O
range	O
,	O
18	O
years	O
)	O
underwent	O
cardiovascular	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
,	O
which	O
was	O
performed	O
to	O
assess	O
cardiac	O
function	I:C0232164
and	O
late	O
gadolinium	I:C2936236
enhancement	I:C2936236
,	O
and	O
T1	O
and	O
T2	O
mapping	O
.	O

Materials	O
and	O
Methods	O
Fifty	O
-	O
three	O
consecutive	O
patients	O
with	O
a	O
biopsy	O
-	I:C1304881
proven	I:C1304881
extracardiac	O
diagnosis	I:C0011900
of	O
systemic	O
sarcoidosis	O
(	O
21	O
men	B:C0025266
;	O
median	O
age	O
,	O
45	O
years	O
;	O
interquartile	O
range	O
,	O
22	O
years	O
)	O
and	O
36	O
normotensive	O
previously	O
healthy	O
control	O
subjects	O
(	O
14	O
men	O
;	O
median	O
age	O
,	O
43	O
years	O
;	O
interquartile	O
range	O
,	O
18	O
years	O
)	O
underwent	O
cardiovascular	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
,	O
which	O
was	O
performed	O
to	O
assess	O
cardiac	O
function	I:C0232164
and	O
late	O
gadolinium	I:C2936236
enhancement	I:C2936236
,	O
and	O
T1	O
and	O
T2	O
mapping	O
.	O

Materials	O
and	O
Methods	O
Fifty	O
-	O
three	O
consecutive	O
patients	O
with	O
a	O
biopsy	O
-	I:C1304881
proven	I:C1304881
extracardiac	O
diagnosis	I:C0011900
of	O
systemic	O
sarcoidosis	O
(	O
21	O
men	O
;	O
median	O
age	O
,	O
45	O
years	O
;	O
interquartile	O
range	O
,	O
22	O
years	O
)	O
and	O
36	O
normotensive	B:C2712122
previously	O
healthy	O
control	O
subjects	O
(	O
14	O
men	O
;	O
median	O
age	O
,	O
43	O
years	O
;	O
interquartile	O
range	O
,	O
18	O
years	O
)	O
underwent	O
cardiovascular	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
,	O
which	O
was	O
performed	O
to	O
assess	O
cardiac	O
function	I:C0232164
and	O
late	O
gadolinium	I:C2936236
enhancement	I:C2936236
,	O
and	O
T1	O
and	O
T2	O
mapping	O
.	O

Materials	O
and	O
Methods	O
Fifty	O
-	O
three	O
consecutive	O
patients	O
with	O
a	O
biopsy	O
-	I:C1304881
proven	I:C1304881
extracardiac	O
diagnosis	I:C0011900
of	O
systemic	O
sarcoidosis	O
(	O
21	O
men	O
;	O
median	O
age	O
,	O
45	O
years	O
;	O
interquartile	O
range	O
,	O
22	O
years	O
)	O
and	O
36	O
normotensive	O
previously	O
healthy	O
control	O
subjects	O
(	O
14	O
men	B:C0025266
;	O
median	O
age	O
,	O
43	O
years	O
;	O
interquartile	O
range	O
,	O
18	O
years	O
)	O
underwent	O
cardiovascular	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
,	O
which	O
was	O
performed	O
to	O
assess	O
cardiac	O
function	I:C0232164
and	O
late	O
gadolinium	I:C2936236
enhancement	I:C2936236
,	O
and	O
T1	O
and	O
T2	O
mapping	O
.	O

Materials	O
and	O
Methods	O
Fifty	O
-	O
three	O
consecutive	O
patients	O
with	O
a	O
biopsy	O
-	I:C1304881
proven	I:C1304881
extracardiac	O
diagnosis	I:C0011900
of	O
systemic	O
sarcoidosis	O
(	O
21	O
men	O
;	O
median	O
age	O
,	O
45	O
years	O
;	O
interquartile	O
range	O
,	O
22	O
years	O
)	O
and	O
36	O
normotensive	O
previously	O
healthy	O
control	O
subjects	O
(	O
14	O
men	O
;	O
median	O
age	O
,	O
43	O
years	O
;	O
interquartile	O
range	O
,	O
18	O
years	O
)	O
underwent	O
cardiovascular	B:C3887460
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
,	O
which	O
was	O
performed	O
to	O
assess	O
cardiac	O
function	I:C0232164
and	O
late	O
gadolinium	I:C2936236
enhancement	I:C2936236
,	O
and	O
T1	O
and	O
T2	O
mapping	O
.	O

Materials	O
and	O
Methods	O
Fifty	O
-	O
three	O
consecutive	O
patients	O
with	O
a	O
biopsy	O
-	I:C1304881
proven	I:C1304881
extracardiac	O
diagnosis	I:C0011900
of	O
systemic	O
sarcoidosis	O
(	O
21	O
men	O
;	O
median	O
age	O
,	O
45	O
years	O
;	O
interquartile	O
range	O
,	O
22	O
years	O
)	O
and	O
36	O
normotensive	O
previously	O
healthy	O
control	O
subjects	O
(	O
14	O
men	O
;	O
median	O
age	O
,	O
43	O
years	O
;	O
interquartile	O
range	O
,	O
18	O
years	O
)	O
underwent	O
cardiovascular	O
magnetic	B:C0024485
resonance	I:C0024485
imaging	I:C0024485
,	O
which	O
was	O
performed	O
to	O
assess	O
cardiac	O
function	I:C0232164
and	O
late	O
gadolinium	I:C2936236
enhancement	I:C2936236
,	O
and	O
T1	O
and	O
T2	O
mapping	O
.	O

Materials	O
and	O
Methods	O
Fifty	O
-	O
three	O
consecutive	O
patients	O
with	O
a	O
biopsy	O
-	I:C1304881
proven	I:C1304881
extracardiac	O
diagnosis	I:C0011900
of	O
systemic	O
sarcoidosis	O
(	O
21	O
men	O
;	O
median	O
age	O
,	O
45	O
years	O
;	O
interquartile	O
range	O
,	O
22	O
years	O
)	O
and	O
36	O
normotensive	O
previously	O
healthy	O
control	O
subjects	O
(	O
14	O
men	O
;	O
median	O
age	O
,	O
43	O
years	O
;	O
interquartile	O
range	O
,	O
18	O
years	O
)	O
underwent	O
cardiovascular	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
,	O
which	O
was	O
performed	O
to	O
assess	O
cardiac	B:C0232164
function	I:C0232164
and	O
late	O
gadolinium	I:C2936236
enhancement	I:C2936236
,	O
and	O
T1	O
and	O
T2	O
mapping	O
.	O

Materials	O
and	O
Methods	O
Fifty	O
-	O
three	O
consecutive	O
patients	O
with	O
a	O
biopsy	O
-	I:C1304881
proven	I:C1304881
extracardiac	O
diagnosis	I:C0011900
of	O
systemic	O
sarcoidosis	O
(	O
21	O
men	O
;	O
median	O
age	O
,	O
45	O
years	O
;	O
interquartile	O
range	O
,	O
22	O
years	O
)	O
and	O
36	O
normotensive	O
previously	O
healthy	O
control	O
subjects	O
(	O
14	O
men	O
;	O
median	O
age	O
,	O
43	O
years	O
;	O
interquartile	O
range	O
,	O
18	O
years	O
)	O
underwent	O
cardiovascular	O
magnetic	O
resonance	I:C0024485
imaging	I:C0024485
,	O
which	O
was	O
performed	O
to	O
assess	O
cardiac	O
function	I:C0232164
and	O
late	B:C2936236
gadolinium	I:C2936236
enhancement	I:C2936236
,	O
and	O
T1	O
and	O
T2	O
mapping	O
.	O

A	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
substudy	O
was	O
performed	O
in	O
40	O
patients	O
(	O
mean	O
follow	O
-	O
up	O
interval	O
,	O
144	O
days	O
±	O
35	O
[	O
standard	O
deviation	O
]	O
)	O
;	O
of	O
these	O
40	O
patients	O
,	O
18	O
underwent	O
anti-inflammatory	O
treatment	I:C0087111
for	O
systemic	O
symptoms	O
.	O

A	O
follow	O
-	I:C1522577
up	I:C1522577
substudy	B:C2603343
was	O
performed	O
in	O
40	O
patients	O
(	O
mean	O
follow	O
-	O
up	O
interval	O
,	O
144	O
days	O
±	O
35	O
[	O
standard	O
deviation	O
]	O
)	O
;	O
of	O
these	O
40	O
patients	O
,	O
18	O
underwent	O
anti-inflammatory	O
treatment	I:C0087111
for	O
systemic	O
symptoms	O
.	O

A	O
follow	O
-	I:C1522577
up	I:C1522577
substudy	O
was	O
performed	O
in	O
40	O
patients	O
(	O
mean	O
follow	O
-	O
up	O
interval	O
,	O
144	O
days	O
±	O
35	O
[	O
standard	O
deviation	O
]	O
)	O
;	O
of	O
these	O
40	O
patients	O
,	O
18	O
underwent	O
anti-inflammatory	B:C0087111
treatment	I:C0087111
for	O
systemic	O
symptoms	O
.	O

Binary	O
logistic	O
regression	O
and	O
receiver	O
operating	O
characteristic	O
curve	O
analyses	B:C0936012
were	O
used	O
to	O
assess	O
discrimination	O
between	O
health	O
and	O
disease	O
;	O
Wilcoxon	O
signed	I:C0871608
rank	I:C0871608
test	I:C0871608
was	O
used	O
to	O
assess	O
the	O
effect	O
of	I:C1518681
treatment	I:C1518681
.	O

Binary	O
logistic	O
regression	O
and	O
receiver	O
operating	O
characteristic	O
curve	O
analyses	O
were	O
used	O
to	O
assess	O
discrimination	O
between	O
health	O
and	O
disease	B:C0012634
;	O
Wilcoxon	O
signed	I:C0871608
rank	I:C0871608
test	I:C0871608
was	O
used	O
to	O
assess	O
the	O
effect	O
of	I:C1518681
treatment	I:C1518681
.	O

Binary	O
logistic	O
regression	O
and	O
receiver	O
operating	O
characteristic	O
curve	O
analyses	O
were	O
used	O
to	O
assess	O
discrimination	O
between	O
health	O
and	O
disease	O
;	O
Wilcoxon	B:C0871608
signed	I:C0871608
rank	I:C0871608
test	I:C0871608
was	O
used	O
to	O
assess	O
the	O
effect	O
of	I:C1518681
treatment	I:C1518681
.	O

Binary	O
logistic	O
regression	O
and	O
receiver	O
operating	O
characteristic	O
curve	O
analyses	O
were	O
used	O
to	O
assess	O
discrimination	O
between	O
health	O
and	O
disease	O
;	O
Wilcoxon	O
signed	I:C0871608
rank	I:C0871608
test	I:C0871608
was	O
used	O
to	O
assess	O
the	O
effect	B:C1518681
of	I:C1518681
treatment	I:C1518681
.	O

When	O
compared	O
with	O
control	O
subjects	O
,	O
patients	O
had	O
higher	O
ventricular	O
volume	O
,	O
higher	O
myocardial	B:C1522564
native	O
T1	O
and	O
T2	O
,	O
and	O
lower	O
longitudinal	O
strain	I:C0243095
and	O
ejection	O
fraction	I:C2700378
(	O
P	O
<	O
.05	O
for	O
all	O
)	O
.	O

When	O
compared	O
with	O
control	O
subjects	O
,	O
patients	O
had	O
higher	O
ventricular	O
volume	O
,	O
higher	O
myocardial	O
native	O
T1	O
and	O
T2	O
,	O
and	O
lower	O
longitudinal	B:C0243095
strain	I:C0243095
and	O
ejection	O
fraction	I:C2700378
(	O
P	O
<	O
.05	O
for	O
all	O
)	O
.	O

When	O
compared	O
with	O
control	O
subjects	O
,	O
patients	O
had	O
higher	O
ventricular	O
volume	O
,	O
higher	O
myocardial	O
native	O
T1	O
and	O
T2	O
,	O
and	O
lower	O
longitudinal	O
strain	I:C0243095
and	O
ejection	B:C2700378
fraction	I:C2700378
(	O
P	O
<	O
.05	O
for	O
all	O
)	O
.	O

Myocardial	B:C1522564
native	O
T1	O
and	O
T2	O
had	O
higher	O
discriminatory	O
accuracy	O
(	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
[	O
AUC	O
]	O
:	O
0.96	O
and	O
0.89	O
,	O
respectively	O
)	O
for	O
separation	O
between	O
control	O
subjects	O
and	O
patients	O
when	O
compared	O
with	O
the	O
standard	O
diagnostic	O
criteria	I:C0679228
(	O
AUC	O
<	O
0.67	O
)	O
.	O

Myocardial	O
native	O
T1	O
and	O
T2	O
had	O
higher	O
discriminatory	O
accuracy	O
(	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
[	O
AUC	O
]	O
:	O
0.96	O
and	O
0.89	O
,	O
respectively	O
)	O
for	O
separation	O
between	O
control	O
subjects	O
and	O
patients	O
when	O
compared	O
with	O
the	O
standard	O
diagnostic	B:C0679228
criteria	I:C0679228
(	O
AUC	O
<	O
0.67	O
)	O
.	O

Native	O
T1	O
was	O
the	O
independent	O
discriminator	O
between	O
health	O
and	O
disease	B:C0012634
(	O
specificity	O
,	O
90	O
%	O
;	O
sensitivity	O
,	O
96	O
%	O
;	O
accuracy	O
,	O
94	O
%	O
)	O
.	O

There	O
was	O
a	O
significant	B:C0441610
reduction	I:C0441610
of	O
native	O
T1	O
and	O
T2	O
in	O
the	O
patients	O
who	O
underwent	O
treatment	O
(	O
z	O
score	O
:	O
-	O
3.72	O
and	O
-	O
2.88	O
;	O
P	O
<	O
.01	O
)	O
but	O
not	O
in	O
the	O
patients	O
who	O
did	O
not	O
(	O
z	O
score	O
,	O
-	O
1.42	O
and	O
-	O
1.38	O
;	O
P	O
>	O
.15	O
)	O
.	O

There	O
was	O
a	O
significant	O
reduction	I:C0441610
of	O
native	O
T1	O
and	O
T2	O
in	O
the	O
patients	O
who	O
underwent	O
treatment	B:C0087111
(	O
z	O
score	O
:	O
-	O
3.72	O
and	O
-	O
2.88	O
;	O
P	O
<	O
.01	O
)	O
but	O
not	O
in	O
the	O
patients	O
who	O
did	O
not	O
(	O
z	O
score	O
,	O
-	O
1.42	O
and	O
-	O
1.38	O
;	O
P	O
>	O
.15	O
)	O
.	O

There	O
was	O
a	O
significant	O
reduction	I:C0441610
of	O
native	O
T1	O
and	O
T2	O
in	O
the	O
patients	O
who	O
underwent	O
treatment	O
(	O
z	O
score	O
:	O
-	O
3.72	O
and	O
-	O
2.88	O
;	O
P	O
<	O
.01	O
)	O
but	O
not	B:C0205160
in	O
the	O
patients	O
who	O
did	O
not	O
(	O
z	O
score	O
,	O
-	O
1.42	O
and	O
-	O
1.38	O
;	O
P	O
>	O
.15	O
)	O
.	O

There	O
was	O
a	O
significant	O
reduction	I:C0441610
of	O
native	O
T1	O
and	O
T2	O
in	O
the	O
patients	O
who	O
underwent	O
treatment	O
(	O
z	O
score	O
:	O
-	O
3.72	O
and	O
-	O
2.88	O
;	O
P	O
<	O
.01	O
)	O
but	O
not	O
in	O
the	O
patients	O
who	O
did	O
not	B:C0205160
(	O
z	O
score	O
,	O
-	O
1.42	O
and	O
-	O
1.38	O
;	O
P	O
>	O
.15	O
)	O
.	O

Conclusion	O
Quantitative	O
myocardial	B:C0027061
tissue	I:C0027061
characterization	O
with	O
T1	O
and	O
T2	O
mapping	O
may	O
enable	O
noninvasive	O
recognition	I:C0814177
of	O
cardiac	O
involvement	I:C0243095
and	O
activity	O
of	O
myocardial	O
inflammation	I:C0027059
in	O
patients	O
with	O
systemic	O
sarcoidosis	O
.	O

Conclusion	O
Quantitative	O
myocardial	O
tissue	I:C0027061
characterization	O
with	O
T1	O
and	O
T2	O
mapping	O
may	O
enable	O
noninvasive	B:C0814177
recognition	I:C0814177
of	O
cardiac	O
involvement	I:C0243095
and	O
activity	O
of	O
myocardial	O
inflammation	I:C0027059
in	O
patients	O
with	O
systemic	O
sarcoidosis	O
.	O

Conclusion	O
Quantitative	O
myocardial	O
tissue	I:C0027061
characterization	O
with	O
T1	O
and	O
T2	O
mapping	O
may	O
enable	O
noninvasive	O
recognition	I:C0814177
of	O
cardiac	B:C0243095
involvement	I:C0243095
and	O
activity	O
of	O
myocardial	O
inflammation	I:C0027059
in	O
patients	O
with	O
systemic	O
sarcoidosis	O
.	O

Conclusion	O
Quantitative	O
myocardial	O
tissue	I:C0027061
characterization	O
with	O
T1	O
and	O
T2	O
mapping	O
may	O
enable	O
noninvasive	O
recognition	I:C0814177
of	O
cardiac	O
involvement	I:C0243095
and	O
activity	O
of	O
myocardial	B:C0027059
inflammation	I:C0027059
in	O
patients	O
with	O
systemic	O
sarcoidosis	O
.	O

Future	O
studies	B:C2603343
will	O
be	O
performed	O
to	O
confirm	O
their	O
role	O
in	O
risk	O
stratification	O
and	O
guidance	O
of	O
clinical	O
management	I:C1516615
.	O

Future	O
studies	O
will	O
be	O
performed	O
to	O
confirm	O
their	O
role	O
in	O
risk	O
stratification	B:C1514983
and	O
guidance	O
of	O
clinical	O
management	I:C1516615
.	O

Future	O
studies	O
will	O
be	O
performed	O
to	O
confirm	O
their	O
role	O
in	O
risk	O
stratification	O
and	O
guidance	B:C0150600
of	O
clinical	O
management	I:C1516615
.	O

Future	O
studies	O
will	O
be	O
performed	O
to	O
confirm	O
their	O
role	O
in	O
risk	O
stratification	O
and	O
guidance	O
of	O
clinical	B:C1516615
management	I:C1516615
.	O

